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INTRODUCTION 
Bacterial conjunctivitis is an inflammation of the 
conjunctiva, characterised by persistent mucopurlent 
discharge and redness of the eye 
1
. It is generally a self-
limiting disease and usually does not cause permanent 
loss of vision or structural damage to eye. Topical anti-
bacterial is used to overcome this disease 
2, 3 
.Bacterial 
conjunctivitis caused by those bacteria which infect the 
eye through various sources of contamination. The most 
common types of bacteria that cause bacterial 
conjunctivitis include Streptococcus pneumonia, 
Staphylococcus aureus, Staphylococcus epidermidis, 
Haemophilus influenza, Moraxella catarrhalis and 
Corynebacterium spp 
4,5
, .Aerococcusviridans, CDC 
coryneform group G, Corynebacterium striatum, 
Haemophilus influenzae, Moraxella catarrhalis, 
Moraxella lacunata, Pseudomonas aeruginosa,       
Staphylococcus aureus, Staphylococcus epidermidis, 
Staphylococcus hominis, Staphylococcus lugdunensis, 
Staphylococcus warneri, Streptococcus mitis group, 
Streptococcus oralis, Streptococcus pneumoniae, 
Streptococcus salivary 
6
. 
Besifloxacin ophthalmic suspension 0.6%w/v was 
approved by US-FDA in 2009. The formulation uses 
Duracite
®
 technology to increase the residence time of 
drug on theocular 
7,8 
.Besifloxacin is a novel 
fluoroquinolone antibiotic for ocular pathogens that are 
currently resistant to present fluoroquinolone antibiotics 
9
. 
Besifloxacin (7-[(3R)-3- aminohexahydro -1H-azepin -1-
y1] – 8 – choloro -1- cyclopropyl – 6-fluoro -1,4-dihydro 
-4-oxo-3-quinolinecarboxylic acid )–(figure 1)is a novel, 
chiral synthetic fluoroquinolone  being developed by 
Bausch & Lomb for the topical treatment of ophthalmic 
infections. Structurally, besifloxacin has an N-1 cyclo-
propyl group, which provides broad- spectrum activity 
against aerobic bacteria 
10
. The main mechanism of 
action of besifloxacin is the inhibition of DNA gyrase 
and topoisomerase-IV enzyme that are involved in 
bacterial transcription replication and separation of 
chromosomal DNA during cell division 
10
. This activity 
is enhanced by a C-8 chloride substituent in besifloxacin, 
which also exhibits improved activity against gram-
positive bacteria relative to older fluoroquinolone while 
still remaining potent efficacy against anaerobic bacteria 
11 
.  
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ABSTRACT 
Besifloxacin is fourth generation ophthalmic fluoroquinolone of synthetic origin, it was approved by the United States Food 
and Drug Administration (USFDA) in May 2009 for the treatment of bacterial conjunctivitis. It is only fluoroquinolone that 
has not been studied for systemic use; it was sold first in United States of America (USA) under the trade name of Besivance® 
ophthalmic suspension 0.6% formulated with Duracite®technology. This review article provides an overview of the 
pharmacology, efficacy and tolerability of besifloxacin suspension in the treatment of bacterial conjunctivitis, along with their 
different analytical techniques.Besifloxacin is a broad spectrum antibiotic active against ocular bacterial pathogen 
Streptococcus pneumonia, Staphylococcus aureus, Staphylococcus epidermidis, Haemophilus influenza, Moraxella catarrhalis 
and Corynebacterium spp.Conjunctival concentration of besifloxacin was reported and found to be Cmax- 62.79µg/ml, AUC0-t -
5569min.µg/ml, MIC90 <0.06-4µg/ml after single dose of besifloxacin ophthalmic suspension 0.6% in rabbit. In two 
randomised, double masked vehicle- control trial study reported the besifloxacin ophthalmic suspension was well tolerated and 
efficacious than vehicles.Besifloxacin was found to be well tolerated in clinical trial however common adverse effects were 
blurred vision (2.1%), bacterial conjunctivitis (1.8%), eye pain (1.5%) and non-specific bacterial conjunctivitis. Besifloxacin 
0.6% ophthalmic suspension was reported to the well tolerated and efficacious in the treatment of bacterial conjunctivitis.There 
were several methods of analysis like UV, HPLC and microbiological for the quantification of besifloxacin.  
Keywords: Besifloxacin, Moxifloxacin, Gatifloxacin, Bacterial conjunctivitis, HPLC Pharmacokinetic 
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Cambau E et al. 
12
 investigated mechanism of action of 
BSF in Streptococcus pneumoniae and Staphylococcus 
aureus and found that BSF inhibit both enzyme 
DNAgyrase and topoisomerase-IV. Microbial data 
reports that besifloxacin have a relatively high potency 
and rapid bactericidal activity against conjunctivitis 
causing agents or bacteria 
13
. However, this review 
article provides an overview of the pharmacologic and 
pharmacokinetic properties, clinical efficacy, and 
tolerability of besifloxacin 0.6% ophthalmic suspension 
along with HPLC and microbiological validation of 
besifloxacin bioassay. 
 
Figure 1: Chemical structure of besifloxacin. 
METHODS OF CITATION 
The reports related to pharmacology, efficacy, 
tolerability and validating methods like HPLC and by 
Bioassay.  Microbiological assay of besifloxacin 
obtained through a search of PubMed, Medline, 
International Pharmaceutical Abstracts , Willey Library 
Online, Science Direct , Drug Review of R & D of 
besifloxacin and searching FDA website using the term 
besifloxacin, besivance, besix, bacterial conjunctivitis, 
HPLC methods of besifloxacin, microbiological assay of 
besifloxacin , mechanism action of besifloxacin, SAR of 
besifloxacin, safety and tolerability of  ophthalmic 
suspension of besifloxacin, spectrum of besifloxacin, 
causative agents of bacterial conjunctivitis, ADR of 
besifloxacin, marketed products of besifloxacin HCL and 
dose administration of ophthalmic suspension of 
besifloxacin.  
PHARMACOKINETIC PARAMETERS 
Ward et al. 
11 
reported after instillation of a single dose of 
0.6% ophthalmic suspension of besifloxacin in rabbit’s 
eye and determined the ocular pharmacokinetic 
parameter of besifloxacin. These ocular pharmacokinetic 
parameter like Cmax, AUC, Mean residence time (MRT) 
of drug were studied in aqueous humours, tears and in 
plasma (Table 1). 
 
Table 1: Pharmacokinetical parameters of besifloxacin ophthalmic suspension of 0.6% concentration after a 
single installation in rabbit ocular tissue 
11 
Site  Cmax(µg/ml) AUC0-t (min. µg/ml) MRT (min.) 
Tears 2756 194, 580 923 
Conjunctiva 62.7900 5569 458 
Aqueous humor 1.6920 125 422 
Plasma 0.0198 2.55 NA 
NA = Not available 
 
Among the plasma, aqueous humours, conjunctiva and 
tears, very low concentration of besifloxacin (<10 µg/ml) 
was found in plasma after single dose, so it confirming 
minimal systemic exposure after ocular administration. 
The drug concentration in conjunctiva was more than 
plasma and aqueous humour and less than the 
concentration obtained in tears. The result of these 
simulation indicated that a thrice daily dosing regimen 
was sufficient to achieve conjunctival besifloxacin 
concentration of 2µg/g that were consistently above the 
MIC90 for most ophthalmologic. 
Prokesh et al. 
14 
evaluated by administrating one drop of 
besifloxacin ophthalmic suspension 0.6% in each eye 3-
times daily for 5-days with a final dosing on 6 
th 
day in a 
subject with bacterial conjunctivitis. In another study a 
single topical ocular administration was given and found 
that the besifloxacin was rapidly absorbed (Tmax=0.5 
hour) and sustained concentration in tears of besifloxacin 
was found to be of <0.05 µg/ml that were maintained 
through 24 hours. The mean plasma concentration was 
12-15 folds lower in human than in the experiment in 
rabbits and monkey. The in-vitro protein binding of 
besifloxacin in human plasma ranges from 38.5% - 
44.0% (Table 2). 
Table 2: Ocular pharmacokinetical parameters of 
besifloxacin ophthalmic suspension 0.6% in human 
tears 
14 
Parameters Value 
Cmax, mean(SD), µg/ml* 610(540) 
Tmax, min. 10 
AUC0-24h, µg.h/g
* 
1232 
Elimination t1/2,h* ~3.4 
Systemic exposure, ng/ml
†
 <0.5 
*Measured in tears of volunteers who received a single ocular 
administration of suspension. 
†Measured in plasma from patients who received besifloxacin 
ophthalmic suspension 3-times daily for 5-days. 
Cmax- Maximum concentration, Tmax- Peak time, AUC - Area 
under curve 
 
CLINICAL SAFETY AND EFFICACY 
The clinical safety and efficacy of 0.6% ophthalmic 
suspension of besifloxacin in the treatment of bacterial 
conjunctivitis was studied and reported by Tepedino et 
al.
8
, Karpeci et al. 
15
, McDonald MB et al. 
16 
Khimdas et 
al. 
17 
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Besifloxacin and Vehicle and others 
Tepedino et al 
8 
, Karpeci et al.
15 
and McDonald MB et 
al.
16 
conducted a prospective, randomised, double 
masked, vehicle-controlled parallel group trial for a 5 
days for evaluating the clinical safety, efficacy and 
microbiological inhibitory action of 0.6% ophthalmic 
suspension of besifloxacin in the treatment of bacterial 
conjunctivitis. 
In their trial study 269 patients were selected for 
treatment (137- Besifloxacin, 132- Vehicle), however 
among them only 256 subjects completed the trial (134- 
Besifloxacin, 122- Vehicle) respectively. Where in the 
culture-confirmed study intent to treat population 
consisted of 118 patients (60-Besifloxacin 0.6% 
ophthalmic suspension and 58-Vehicle controlled) 
respectively. In this study the female subjects were 
(60.2%) in which white were 82.5%, with mean age 34.2 
years
8, 15
.
 
During this trial more patients were received 
0.6% ophthalmic suspension of besifloxacin, as 
compared to vehicle. The clinical resolution of the 
baseline infection at visit -3 was found to be 
[44/60(73.3%) vs. 25/58 (43.1%) respectively, P<0.001]. 
The result as compared with vehicle in visit 3, the rate of 
bacterial eradication was also greater with besifloxacin 
suspension [53/60 (88.3%) vs. 35/58 (60.3%); P<0.001, 
(Table 3). 
The adverse event was not differ significantly between 
the two groups [69/37 (50.4%)] and [70/32 (53.0%)].The 
most common ocular adverse effects were eye pain, 
blurred vision, eye irritation and visual acuity.  However, 
Karpeci et al. 
15
 studied and reported that 0.6% 
ophthalmic suspension of besifloxacin, administered 3 
times daily for 5 days was both efficacious and well 
tolerated as compared with vehicle in the treatment of 
patients with bacterial conjunctivitis. However, treatment 
with besifloxacin that was reported by Karpeci et al. 
were to be well tolerated, with no apparent differences 
compared with vehicle in terms of clinically significant 
changes in visual acuity or treatment-emergent events on 
bio microscopy or direct ophthalmoscopy. In addition, 
besifloxacin ophthalmic suspension 0.6% administered 
two- times daily for 3-days was clinically more effective 
than the vehicle alone for bacterial conjunctivitis.
 
 
Table: 3. Investigators rating of clinical signs and symptoms in the culture conformed to treat population.
15 
 
Clinical sign and symptom 
Visit 2 (Day 4) Visit3(Day 8) 
Besifloxacin 
 (n = 60) 
Vehicle 
 (n =56) 
Besifloxacin  
(n = 60) 
Vehicle  
(n = 56) 
Ocular discharge                          P = 0.008                       P = 0.003  
Absent 36 (60) 26 (46.4) 54(90) 37(66.1) 
Mild 20 (33.3) 18(32.1) 5(8.3) 15(26.8) 
Moderate 4 (6.7) 11(19.6) 1(1.7) 3(5.4) 
Severe 0 1(1.8) 0 1(1.8) 
Bulbar conjunctival injection P = 0.014 P = 0.013 
Normal 24 (40) 13 (23.2) 45(75) 30(53.6) 
Trace 27(45) 30(53.6) 11(18.3) 21(37.5) 
Moderate 8(13.3) 9(16.1) 3(5) 2(3.6) 
Severe 1(1.7) 4(7.1) 1(1.7) 3(5.4) 
P value calculated by C.- Mantel Haenszel test. 
 
However, Tepedino et al. found 0.6% ophthalmic 
suspension of besifloxacin to be well tolerated in patients 
with bacterial conjunctivitis. Rate of absence of ocular 
discharge and eradication of the baseline infection were 
higher with 0.6% ophthalmic suspension of besifloxacin 
as compared to the vehicle. On the basis of earlier 
reporting Khimdas et al.
17
concluded that the besifloxacin 
is safe and efficacious for the treatment of bacterial 
conjunctivitis in patients without any bacterial resistance. 
Malohotra et al.
18
 also conducted randomized, 
multicentre, double masked, vehicle controlled, parallel 
group study on 518 selected subjects with mean age of ≥ 
1 years. In trial study, patients were randomized into 2:1 
to treatment with besifloxacin 0.6% ophthalmic 
suspension and vehicle for 7 days, through instilled one 
drop to infected eyes. They reported that besifloxacin 
0.6% ophthalmic suspension is safe in patient to treat 
bacterial conjunctivitis infected eyes, when used three 
times daily for seven days. 
COMPARISION WITHDIFFERENT 
FLUOUROQUINOLONEAND VEHICLE 
McDonald MB et al.
16 
conducted a prospective, 
randomized, double-masked, active-controlled, parallel-
group, non-inferiority trial to compared the clinical and 
antimicrobial efficacy of 0.6% ophthalmic suspension of 
besifloxacin and 0.5% ophthalmic suspension   of 
moxifloxacin, by administered both 3 times daily for 5 
days, in the treatment of bacterial conjunctivitis. 
However, McDonald MB et al. found that 0.6% 
ophthalmic suspension of besifloxacin to be noninferior 
in tolerability and efficacy to 0.5% ophthalmic solution 
of moxifloxacin in the treatment of bacterial 
conjunctivitis. There were no significant differences 
found in rates of absence of ocular discharge and 
eradication of the baseline microbial infection between 
the two treatment groups. 
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Torkildsen G et al
 19 
conducted a trial to compared the 
pharmacokinetic parameter of besifloxacin, gatifloxacin 
and moxifloxacin and found that these fluoroquinolone 
were well tolerated in patients. 
Silverstein et al. 
20
   reported that besifloxacin 
ophthalmic suspension 0.6% administered twice daily for 
3 days leads significantly higher rates of clinical 
resolution and bacterial eradication as compared with 
vehicle and also was well tolerated, Table 4. The same 
was also reported by Karpeci et al.
15,
 Tepedino et al.
8
 and 
McDonald MB et al.
16,
 (Table 5) but days of study was 
differ among them. Besifloxacin ophthalmic suspension 
was associated with significantly higher rates of clinical 
resolution compared with vehicle at visit-2 for infection 
with H. Influenza, S.aureus, and S. epidermids who 
significantly shows higher rates of bacterial eradication 
at each visit of infection 
21-24 
.In addition, besifloxacin 
MIC90 values against these species were found several 
folds lower than those of others comparator 
fluoroquinolone like moxifloxacin, gatifloxacin, 
ciprofloxacin, azithromycin, tobramycin, and 
vancomycin(Table 6).  
 
Table: 4. Treatment emergent ocular adverse event.
20 
                      Study eyes, no (%)      All treated eyes no, (%)  
 Variable                   Besifloxacin 
ophthalmic         
suspension (n = 94) 
Vehicle 
(n = 157) 
 
 
P 
Besifloxacin 
ophthalmic         
suspension (n = 157) 
Vehicle 
(n = 154) 
 
 
p 
Total no. of AE 4 8 9 17 
Eyes with ≥ 1 AE  4(4.3)       8(8.2) 0.373 9(5.7) 17(11) 0.104 
Specific AEs, no (%) 
Conjunctivitis 
bacterial 
0 0 1 3(1.9) 5 0.499 
Conjunctivitis 2(2.1) 3(3.1) 1 3(1.9) 4 0.721 
Conjunctivitis, 
allergic 
1(1.1) 1(1.0) 1 2(1.3) 1 1 
Conjunctiva - l 
hypermia 
0 1(1.0) 1 0 1 0.495 
Instillation – site 
pain 
1(1.1) 0 1 0 2 0.244 
Corneal staining 0 1(1.0) 1 0 2 0.244 
 
 
Table 5: Summary of phase III clinical efficacy studies of besifloxacin ophthalmic suspension 0.6% 
8, 15, and 16 
Efficacy, n/N (%) 
Authors /study 
design 
Intervention  Clinical  Microbiologic  Adverse effect  
Karpecki  et al  
15
., 
MC, R, DM, VC, PG 
,Prospective 
Besifloxacin TID for 
5 days (n= 137) 
Vehicle TID for 5 
days (n= 132) 
44/60 (73.3) 
 
25/58 (43.1) 
53/60 (88.3)  
 
35/58 (60.3) 
>5% eye pain (10.5% 
BSF, 6.9% 
vehicle),blurred vision 
,eye irritation 
Tepedino et 
8
al.MC, 
R, DM, VC, PG, 
Prospective 
Besifloxacin TID for 
5 days (n= 473) 
Vehicle TID for 5 
days (n= 484) 
90/199 (45.2) 
 
63/191 (33.0) 
182/199 (91.5) 
 
114/191 (59.7) 
Blurred vision(1.2% 
and 2.2%), eye 
irritation(1.1% and 
0.4%) , bacterial 
conjunctivitis (0.8% 
and 2.1%) 
Mc Donald et al.
 
16
MC, R, DM, AC, 
PG, prospective, 
non-inferiority 
Besifloxacin TID for 
5 days (n= 582) 
moxifloxacin TID 
for 5 days (n= 579) 
147/252 (58.3) 
 
167/281 (59.4) 
235/252 (93.3) 
 
256/281 (91.1) 
Blurred vision (1% and 
0.5%), eye pain (0.6% 
and 1.1%), eye 
irritation (0.3% and 
1.4%) 
MC= Multi centre, R =Randomized, DM= Double masked, VC = Vehicle controlled,   PG = Parallel group, AC = Active controlled. 
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Table 6: In-vitro activity of besifloxacin and other antibacterial agentagainst isolated bacterial pathogen. 
21-24 
MIC90, µg/ml 
Species B M G C A T V 
All species (n= 178) 0.25 0.25 0.5 2 128 16 ND 
 Gram positive (n=104) 0.25 0.5 0.5 2 256 32 2 
Gram negative (n = 74) 0.06 0.06 0.06 0.06 4 2 ND 
H.influenzae (n= 74)  0.06 0.06 0.03 0.015 4 2 ND 
S.aureus (n =24) 0.5 2 2 8 128 1 1 
S.epidermidis (n = 18) 0.5 4 2 64 >256 8 2 
S. pneumoniae(n= 16) 0.12 0.25 0.5 2 0.25 32 0.5 
B – Besifloxacin, M – Moxifloxacin, G – Gatifloxacin, C – Ciprofloxacin, A – Azithromycin, T – Tobramycin, V – Vancomycin 
 
DOSAGE REGIMEN AND ADMINISTRATION 
Besivance® 
25 
Besifloxacin ophthalmic suspension 0.6% 
w/v) is sterile topical ophthalmic eye drop of quinolone 
derivative. It is indicated for the treatment of bacterial 
conjunctivitis caused by susceptible isolates of bacteria. 
Besivance® and Besix® two different marketed brands 
was formulated by ‘Duracite’ technology containing 
0.6% sterile ophthalmic suspension of besifloxacin 
which are available in 5 ml of sterile packing. Each ml of 
0.6% suspension contains 6.63 mg of besifloxacin 
hydrochloride equivalent to 6 mg of the drug. The 
suggested dose is one drop to the bacterial infected eye, 3 
times daily for 7 days 
25 
. Besifloxacin is only 
recommended for topical ophthalmic use and should not 
be injected sub conjunctively, nor should it be introduced 
directly into the anterior chamber of the eye. Patients 
who have signs and symptoms of bacterial conjunctivitis 
should not wear contact lenses. During the time of 
administration invert the close bottle, as well as 
suspension bottle must be shake once before use. 
 
ANALYSIS OF BESIFLOXACIN 
Arnold et al. 
26 
quantitatively determined besifloxacin in 
human tear by liquid chromatography by using 
sparfloxacin as the internal standard. Calibration 
standard were prepared by spiking schirmer strips 
containing the artificial tear solution with known 
concentration of besifloxacin. In this study tear sample 
was collected from 64 healthy subject following topical 
ocular administration of 0.6% besifloxacin hydrochloride 
in both eyes with the aid of spiking schirmer strips and 
then analyzed by LC/MS/MS. This artificial tear strip 
was weighed before and after tear collection and the test 
strip were store at −200C until the sample were analyzed. 
However, the reported quantitative analysis of 
besifloxacin in human tear sample was found to 
maximum level was 610±540 µg/g after topical 
administration of 0.6% ophthalmic suspension and tear 
sample were collected and analyzed 24 hours after 
dosing, the method was précised and economical with 
short run time 4 minutes and applied for topical ocular 
pharmacokinetic of besifloxacin. 
Costa C. N. et al. 
27
 reported the development and 
validation of microbiological assay method that was 
compared with high performance liquid chromatography 
(HPLC) method. The study was based on the inhibitory 
effects of besifloxacin on the strain of Staphylococcus 
epidermidis (ATCC1228). The standardization procedure 
was based on the protocol of Brazilian Pharmacopoeia-
2010and USP-2009 (Table 7).In themicrobiological 
study reported by O,Brien TP 
28
 shows a relatively high 
potency and rapid bactericidal activity for besifloxacin 
against ocular pathogen especially resistant 
staphylococcal species. All the HPLC methods were 
validated in their study according to USP-34, 2011 and 
International conference on Harmonization guidelines 
(ICH), 2005
29.
 
 
Table 7: Evaluation by HPLC and microbiological 
method of BSF ophthalmic suspension after exposure 
to UVA light.
27 
                                                             
Time (min.) 
BSF ophthalmic suspension % 
Microbiological assay HPLC 
0 100 100 
60 91.5 91 
120 81.4 78 
180 74.7 66 
240 69.1 60 
300 60.7 53 
 
CONCLUSION 
Besifloxacin is a new broad-spectrum, bactericidal, 
topical ophthalmic fluoroquinolone approved for the 
treatment of bacterial conjunctivitis. Besifloxacin 
ophthalmic suspension was well tolerated in patients 
with a minimal ocular adverse effect. In addition to its 
broad spectrum of activity, clinical safety, efficacy and 
good tolerability of besifloxacin having also anti-
inflammatory activity through inhibition of pro-
inflammatory cytokines 
30
 and also through inhibition of 
the nuclear factor KB and mitogen activated protein 
kinase pathway. The low minimum inhibitory 
concentration and high attainment of pharmacodynamics 
target with besifloxacin may contribute to a lower risk 
for the emergence for the bacterial resistance, although 
further studies are required. Fluoroquinolone, 
particularly besifloxacin, gatifloxacin and moxifloxacin 
have become important treatment option for common 
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ocular bacterial infection due to their broad spectrum 
bactericidal activity and low toxicity. Besifloxacin 
ophthalmic suspension 0.6% provides safe and 
efficacious treatment for bacterial conjunctivitis. The 
factor leading to bacterial resistance diminished, which 
always besifloxacin to be a favorable treatment option. 
We also summarized the different Pharmacokinetical 
data and their analysis with different analytical methods 
like microbiological and HPLC etc.  
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